Official title and information are available only for Plus and Premium subscribers.
Patent Pending Neuroaid (also NeuroAiD, MLC 601, or MLC 901) is a claimed treatment for stroke sold by Moleac Pte Ltd, a biopharmaceutical company in Singapore. There are two versions: Neuroaid (MLC601) and Neuroaid II (MLC901), with differing blends of ingredients.[1] The ingredients total 14 for both, with nine derived from plants and five from animals.